FDA Pregnancy Drug Categories (The Old System - A, B, C, D, X)

Category A

• Definition: Adequate, well-controlled studies in pregnant women show no risk to the fetus in the first trimester (and no evidence of risk in later trimesters).
• Examples: Folic acid, Levothyroxine (at normal doses), certain vitamins
• Implication: Considered safe for use in pregnancy.

Category B

• Definition: Animal studies show no fetal risk, but no adequate human studies exist; OR animal studies showed adverse effects but adequate human studies showed no risk.
• Examples: Metformin, Amoxicillin, Paracetamol (acetaminophen), Insulin, Ondansetron
• Implication: Generally considered safe based on available data.

Category C

• Definition: Animal studies show adverse fetal effects, but no adequate human studies; or no animal or human studies available. Benefits may justify use despite potential risks.
• Examples: Fluconazole (single dose), most antihypertensives (e.g., amlodipine), many antidepressants (SSRIs early in pregnancy)
• Implication: Use only if the potential benefit justifies the potential risk to the fetus. The largest group of drugs.

Category D

• Definition: There is positive evidence of human fetal risk, but benefits may be acceptable in life-threatening situations or serious disease.
• Examples: Phenytoin, Valproate, Tetracycline, Lithium, Alcohol (if labeled), ACE inhibitors (2nd/3rd trimester)
• Implication: Use only when no safer alternative exists.

Category X

• Definition: Studies (animal or human) show fetal abnormalities, or there is evidence of fetal risk based on reports, and the risks clearly outweigh any benefit.
• Examples: Thalidomide, Isotretinoin (Accutane), Warfarin, Methotrexate, Statins, Misoprostol (for non-obstetric use), Finasteride
• Implication: Absolutely contraindicated in pregnant women or women who may become pregnant.

The Big Change - PLLR (2015)

Why the change?

• The letter categories were oversimplified and often misleading - a "C" drug could mean animal data showed harm, or simply that no data existed at all, both very different situations.
• Clinicians and patients were making assumptions based on letter grades rather than actual risk-benefit analysis.

What replaced it?

Key features of the PLLR:

• Requires narrative text with actual human data when available
• Must reference pregnancy exposure registries if they exist
• Labels must be updated when new safety information emerges
• Applies to all prescription drugs approved after June 30, 2001 (phased in by 2018)
• OTC (over-the-counter) drug labels were NOT changed under this rule

Quick Summary Table

What is the PLLR?

Why Was It Introduced?

• A "Category C" could mean animal studies showed harm OR simply that no data existed - two completely different scenarios grouped under one letter.
• Letters gave a false sense of precision and led to oversimplified prescribing decisions.
• The old system did not address lactation in any structured way.
• There was no requirement to include data on males of reproductive potential (some drugs affect sperm or fertility in men too).
• Labels were rarely updated with new evidence once approved.

The Three Sections Under PLLR

Section 8.1 - Pregnancy (includes Labor & Delivery)

a) Pregnancy Exposure Registry

• Only required if a registry exists for that drug.
• A pregnancy exposure registry is a study that tracks outcomes (birth defects, miscarriage, neonatal complications) in women who took the drug during pregnancy.
• The label must state how to enroll in the registry.
• Purpose: generate real-world human safety data over time.
• Example: The Antiretroviral Pregnancy Registry tracks HIV drug use in pregnant women.

b) Risk Summary

• Presented as a narrative paragraph (not a letter).
• Must include:
  • Summary of known risks from human studies (highest priority)
  • Summary of animal study findings
  • Pharmacological data (what is known about the drug's mechanism and how it could affect fetal development)
  • Background risk statement: e.g., "In the U.S. general population, the estimated background risk of major birth defects is 2-4% and of miscarriage is 15-20%." This context helps clinicians compare the drug's risk to the baseline.

c) Clinical Considerations

• The most practically useful section for prescribers. Covers:
  • Disease-associated risk: What happens if the mother's condition goes untreated? (e.g., uncontrolled epilepsy is itself dangerous to the fetus)
  • Dose adjustments during pregnancy (pharmacokinetics change in pregnancy - increased renal clearance, altered volume of distribution)
  • Maternal adverse reactions specific to pregnancy
  • Fetal and neonatal adverse reactions (e.g., neonatal withdrawal for opioids, neonatal heart block for anti-Ro antibody-associated drugs)
  • Labor and delivery information (formerly a separate section 8.2 under the old rule)

d) Data

• The raw supporting data behind the Risk Summary and Clinical Considerations.
• Includes summaries of specific animal studies, human epidemiological data, case series, etc.
• More technical in nature, intended for researchers and specialists.

Section 8.2 - Lactation (formerly "Nursing Mothers")

a) Risk Summary

• States whether the drug is present in human breast milk.
• Describes effects on:
  • Milk production (some drugs reduce or increase milk supply, e.g., dopamine antagonists increase prolactin)
  • The breastfed infant (exposure dose, potential toxicity)
• Includes the risk-benefit statement - a recommendation on whether breastfeeding should continue, be avoided, or requires monitoring.

b) Clinical Considerations

• How to minimize infant exposure (e.g., pump and discard, time feeds away from peak drug concentration)
• What adverse effects to monitor in the infant
• Drug-specific advice (e.g., for a drug excreted heavily in milk, recommend monitoring infant serum levels)

c) Data

• Technical information: relative infant dose (RID), milk-to-plasma ratio, pharmacokinetic data in lactating women, infant plasma concentrations if studied.
• An RID < 10% is generally considered acceptable for breastfeeding.

Section 8.3 - Females and Males of Reproductive Potential (NEW section - did not exist before)

a) Pregnancy Testing

• States if pregnancy testing is required or recommended before starting the drug.
• Especially important for drugs with known embryo-fetal toxicity (teratogens).
• Example: Isotretinoin requires two negative pregnancy tests before prescribing.

b) Contraception

• States whether contraception is required during and/or after treatment.
• Specifies the type of contraception if relevant (e.g., some drugs interfere with hormonal contraceptives, requiring a barrier method as backup).
• States the duration - how long after stopping the drug contraception must continue (important for drugs with long half-lives or active metabolites).
• Example: Lenalidomide (a thalidomide derivative) requires two forms of contraception.

c) Infertility

• States if the drug has known or suspected effects on fertility in women or men.
• Covers effects on sperm count, motility, ovarian reserve, etc.
• Important: This applies to male patients too - e.g., methotrexate may affect spermatogenesis.

Implementation Timeline

Old vs New: Side-by-Side Comparison

Practical Implications for Clinicians

1. More nuanced prescribing - instead of "it's a Category C, use with caution," the label now tells you exactly what studies exist and what specific risks were found.
2. Better counseling - you can quote actual risk data to patients rather than vague letter categories.
3. Untreated disease risk included - the label now contextualizes the risk of the drug against the risk of not treating the condition.
4. Male patients not forgotten - for chemotherapy, immunosuppressants, and other drugs, the 8.3 section tells you if a male patient needs to use contraception or freeze sperm before treatment.
5. Breastfeeding decisions more informed - detailed RID and infant monitoring data in 8.2 help rather than a blanket "avoid during breastfeeding."